The U.S. House passed a bill late last week limiting cost-sharing for insulin under private health insurance and Medicare Part D.
H.R. 6833 caps cost-sharing under private health insurance for a month’s supply of selected insulin products at $35 or 25% of a plan’s negotiated price (after any price concessions), whichever is less, beginning in 2023. The bill also caps cost-sharing under the Medicare prescription drug benefit for a month’s supply of covered insulin products at $35 beginning in 2023.
The U.S. House passed a bill late last week limiting cost-sharing for insulin under private health insurance and Medicare Part D.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
